OraSure Technologies Inc (OSUR)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

150 WEBSTER ST BETHLEHEM, PA 18015

OraSure Technologies is engaged in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Co. also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Co.'s diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. Co.'s products are sold to clinical laboratories, hospitals, clinics, and physicians' offices.

Data as of 2020-09-12
Market Cap809.326 Million Shares Outstanding71.558 Million Avg 30-day Volume3.009 Million
P/E Ratio Dividend Yield EPS-0.03
Price/Sales5.524 Price cash flow ratio222.4 Price free cash flow ratio-98.9
Book Value5.33 Price to Tangible Book2.27 Alpha0.02
Short Interest Ratio % Short Interest to Float R-squared0.0127
BETA0.509073 52-week High/Low19.75 / 5.23 Stddev0.193013
View SEC Filings from OSUR instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 0 0 (0.0%) 0 (0.0%)
Funds Holding: 191 162 17.9% 55 (3.59%) 38 (2.43%) 44.74%
13F shares: 68.069 Million 55.905 Million 21.76% 25.005 Million 17.694 Million 41.32%
% Ownership 95.1243 89.0948 6.77% 34.943 28.1977 23.92%
New Positions: 47 24 95.83% 24 12 100.0%
Increased Positions 69 49 40.82% 17 6 183.33%
Closed Positions 17 32 -46.88% 7 12 -41.67%
Reduced Positions 47 56 -16.07% 9 15 -40.0%
Total Calls 171.465 Thousand 64.574 Thousand 165.53% 106.2 Thousand 12.2 Thousand 770.49%
Total Puts 124.001 Thousand 69.451 Thousand 78.54% 73.5 Thousand 43.3 Thousand 69.75%
PUT/CALL Ratio 0.72 1.08 -33.33% 0.69 3.55 -80.56%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding OSUR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OSUR BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DATIN JAMES A DIRECTOR

16,203 2020-06-23 3

MARMORA LELIO DIRECTOR

7,015 2020-06-01 2

SHULKIN DAVID DIRECTOR

15,542 2020-05-18 3

CELANO MICHAEL DIRECTOR

66,942 2020-05-15 1

LANCASTER RONNY B DIRECTOR

23,830 2020-05-15 1

PATRICK CHARLES W DIRECTOR

58,446 2020-05-15 1

HOBBS EAMONN P DIRECTOR

34,355 2020-05-15 1

ASPINALL MARA G. DIRECTOR

26,760 2020-05-15 1

NIBAUER LISA EVP & BU LEAD - INFECTIOUS

0 2020-05-11 2

CUCA ROBERTO CFO

91,353 2020-05-07 2

ZEZZO II ANTHONY EVP & BU LEAD - INFECTIOUS

227,867 2020-02-01 1

JERRETT JACK E SVP & GENERAL COUNSEL

133,508 2020-02-01 1

TANG STEPHEN S PHD PRESIDENT AND CEO

199,763 2020-02-01 1

MILLER MICHELE MARIE VP, FINANCE AND CONTROLLER

14,861 2020-02-01 1

WEBER KATHLEEN GALLAGHER EVP & BU LEAD - MOLECULAR

106,544 2020-02-01 1

SARIN ARADHANA DIRECTOR

16,865 2019-05-21 0

REED MICHAEL SVP R&D AND CSO

49,217 2019-04-18 0

KUNA MARK L SEE REMARKS

  • Officer
No longer subject to file 2018-10-22 0

SPAIR RONALD H COO & CFO

  • Officer
  • Director
No longer subject to file 2018-06-08 0

MICHELS DOUGLAS A PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2018-03-31 0

SMITH BRIAN EVP & BU LEAD - MOLECULAR

  • Officer
18,075 2018-02-15 0

PRINGLE ROGER L

  • Director
No longer subject to file 2017-05-15 0

WATSON DOUGLAS G

  • Director
No longer subject to file 2016-11-13 0

WHITTERS ERIC SVP, RESEARCH AND DEVELOPMENT

  • Officer
9,857 2015-02-03 0

OSTROV GERALD M

  • Director
39,346 2014-05-22 0

LEE STEPHEN R EXEC. VP & CSO

  • Officer
55,815 2014-02-01 0

GOLDSTEIN JACK

  • Director
36,000 2011-02-01 0

MENDEZ MANUEL O. VP MARKETING & SALES

  • Officer
13,930 2010-01-27 0

FORMICA P MICHAEL EXEC. VP & GM CRYO. SYS. DIV.

  • Officer
147,874 2009-08-19 0

ZACK JOSEPH E EXEC. VP - MKTG. & SALES

  • Officer
58,050 2008-01-26 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments